home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630046.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
2KB
|
35 lines
Document 0046
DOCN M9630046
TI Interleukin 12 in combination with anti-interleukin 10 reverses graft
prolongation after portal venous immunization.
DT 9603
AU Gorczynski RM; Hozumi N; Wolf S; Chen Z; Department of Surgery,
University of Toronto, Canada.
SO Transplantation. 1995 Dec 15;60(11):1337-41. Unique Identifier :
AIDSLINE MED/96106497
AB Portal venous pretransplantation transfusion augments allogeneic skin
graft survival in mice transplanted across multiple minor
histocompatibility barriers. We have shown in earlier studies that this
is correlated with preferential activation for production of type-2
cytokines (interleukin [IL]-4 and IL-10) and decreased production of
type-1 cytokines (IL-2 and interferon-gamma). We show that recombinant
IL-12, in association with anti-IL-10 monoclonal antibody, can reverse
in vivo the graft prolongation afforded by portal venous immunization
and the altered cytokine production that follows. These alterations are
in turn associated with increased expression of messenger RNA for
interferon-gamma, IL-2, and IL-12 and decreased expression of IL-4,
IL-10, and IL-13, as determined by non-quantitative polymerase chain
reaction using cells obtained from lymph nodes draining the graft.
Recombinant IL-12 in vitro also produces dose-related inhibition of
activation for production of type-2 cytokines.
DE Animal Cytokines/GENETICS/*METABOLISM Gene Expression *Graft Survival
Immunization Injections, Intravenous Interleukin-10/*PHYSIOLOGY
Interleukin-12/*ADMINISTRATION & DOSAGE Isoantigens/ADMINISTRATION &
DOSAGE Lymphocyte Transformation Mice Mice, Inbred BALB C Mice,
Inbred C3H Portal Vein Recombinant Proteins RNA, Messenger/GENETICS
Skin Transplantation/*IMMUNOLOGY Th2 Cells/*IMMUNOLOGY JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).